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1. Introduction 
 
1.1. Anatomy of the prostate gland 
 
The prostate gland consists of three types of cells. The secretory or epithelial cells 
produce a wide range of substances, mostly enzymes, which help in the mobility and 
feeding of the sperm. The stroma is composed of smooth muscle cells and 
fibroblasts. The prostate has a blood supply and somatic, parasympathetic and 
sympathetic nerve fibres. The perineural spaces around these nerve fibres are 
unique to the prostate gland and cancer cells can migrate there.  
The exocrine secretion of the prostate gland consists of many different enzymes and 
proteins. Some are concerned with the liquefaction of the sperm, while others 
facilitate the penetration of the sperm into the zona pellucida of the egg.  
Circulating hormones produced by the testicle and the adrenal glands influence the 
prostate. Luteinizing-hormone releasing hormone, growth hormone and prolactin may 
also have influence on the prostate gland. 
Through a simple diffusion, androgens and other steroid hormones enter the prostate 
epithelial cell. This event activates a pathway and results to the stimulation of cell 
proliferation, division, growth and secretion of the prostate gland.  
The most primitive cell in the prostate gland is a stem cell which, - under the 
influence of androgens - develops into an intermediate cell type and finally into a 
mature epithelial cell. These mature cells are strongly androgen-dependent, a lack of 
androgen causes apoptosis. This event is important for the maintenance and the 
integrity of organs. A balance between cellular proliferation and apoptosis is required 
for the healthy growth of the prostate gland (Newling 1999). 
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1.2.  Prostate cancer  
 
1.2.1. Epidemiology 
 
Prostate cancer is the most common malign neoplasm in male Austrians, followed by 
lung cancer and colorectal cancer (Statistik Austria a). In 2006, 26% of the diagnosed 
tumors of men were located in the prostate (Statistik Austria b). In 2008, prostate 
cancer ranked third in cancer mortality, exceed by lung and colorectal cancer. 1184 
Austrian men died that year from this disease (Statistik Austria c). 
 
The incidence of prostate cancer is intensely increasing since 1993. One reason for 
this development is the prostate specific antigen (PSA) screening, which started in 
Austria for healthy men in the beginning of the 1990s. Nowadays, half of the 
carcinomas are diagnosed at an early stage, even in asymptomatic men, because of 
PSA-screening. However, the mortality rate stays nearly the same (Hackl 2004; 
Vutuc et al. 2005). 
Another reason for the increase of the incidence is a change in the age structure 
towards higher proportions of older people (Alexander 1999) because an established 
risk factor for prostate cancer is advanced age, besides ethnic origin, country of 
residence and family history (Alexander 1999; Gallagher and Fleshner 1998; Johns 
and Houlston 2003; Hackl 2004). The frequency of this disease rises extremely from 
55 years of age onwards. One out of 400 men aged between 55 and 65 suffers from 
a diagnosed prostate cancer (Hackl 2004). 
The difference in incidence between US-American men and Chinese men 
demonstrates the importance of the ethnic origin. The incidence among US-American 
men is 90-fold higher than among Chinese men, which hold the lowest incidence and 
mortality rate together with the Japanese population.  
The highest incidence and mortality rate in the world is among the black population in 
the USA, which is about 35% higher than in whites (Parkin, Bray, and Devesa 2001; 
Alexander 1999). 
The rates of Japanese immigrants to the US are intermediate between their original 
and host communities. They rise with the number of generations spent in the US 
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(Alexander 1999), but the rates reach only half of those for white men living in the 
same areas (Gallagher and Fleshner 1998).  
 
1.2.2. Diagnosis, PIN, grading systems and therapy 
 
The methods to diagnose prostate cancer are: elevated serum PSA level, digital 
rectal examination, transrectal ultrasound imaging and biopsy. However, an elevated 
PSA level is not necessarily a sign of prostate cancer. The increase may be caused 
by other circumstances (Selley et al. 1997). 
 
As a histological precursor of cancer, prostatic intraepithelial neoplasia (PIN) is 
verified. It can be divided into low-grade and high-grade (the pre-invasive stage of 
invasive carcinoma) PIN. It mostly starts in the third decade of life and turns into a 
carcinoma ten or more years later. It is characterized by cytological and architectural 
abnormalities.  
Most prostatic carcinomas are located in the peripheral zone of the prostate. This is 
also the hotspot for PIN. In high-grade PIN, the basal layer cells are disrupted 
(Bostwick 1999).   
 
The tumor tissue from a biopsy or a prostatectomy can be classified with the Gleason 
grading system, which is a numeric system used for prostate cancer grading based 
on a study of the Veterans Administration Cooperative Urological Research Group 
(VACURG). It depends only on the architectural characteristics of the tumor 
(Bostwick 1999; Köllermann and Sauter 2009; Gandellini, Folini, and Zaffaroni 2009). 
The malignancy correlates significantly with the histological pattern of prostate 
cancer. 
Gleason found in 1966 that more than 50% of the carcinomas contained two or more 
patterns and therefore showed heterogeneity. The determinant factor is the degree of 
glandular differentiation (see Figure 1), reflecting tumor heterogeneity by assigning a 
primary pattern for the dominant (or most prevalent) grade and a secondary pattern 
(at least 5% of the tumor) for the non-dominant grade. The histological score is 
derived by adding these two patterns.  
Two is the lowest possible Gleason score. The primary and the secondary pattern 
Gleason grade is one (well-differentiated). When both grades are 5 (undifferentiated), 
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the highest score of 10 is the result. The grade of the first pattern is doubled if no 
secondary pattern exists. For example, the total Gleason score is 6 (3+3) when more 
than 95% of a tumor show Gleason grade 3. 
 
Figure 1. Original Gleason System 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Because only a small part of the tumor can be examined with a biopsy, the Gleason 
score in a prostatectomy preparation is often higher than the score obtained in the 
biopsy. 
 
The Gleason grade can predict the biologic behaviour of a prostate cancer very well, 
including invasiveness and metastatic potential (Bostwick 1999; Epstein 2009; 
Gandellini, Folini, and Zaffaroni 2009; Gleason and Mellinger 1974; Mellinger, 
Gleason, and Bailar 1967). 
Many new methods have extended the knowledge about prostate cancer since the 
introduction of the Gleason grading system in 1966. Examples are the prostate 
 5 
 
specific antigen testing, the transrectal ultrasound-guided prostate needle biopsy and 
the immunohistochemistry for basal cells. These achievements led to a change in the 
classification of prostate cancer and to the detection of new prostate cancer variants.  
The Gleason grading system was updated in 2005 at a consensus conference of 
international experts in urological pathology, under the auspices of the International 
Society of Urological Pathology (ISUP; Epstein 2009). 
 
The second grading system that is often used is the TNM classification for cancer in 
general. It describes the anatomical extent of a cancer and is based on the 
determination of three components. T is the abbreviation for tumor. The subsequent 
number describes the extent of the primary tumor. TX implies that a primary tumor 
cannot be assessed and T0 indicates no evidence of a primary tumor.  
In T1 classification level, the tumor is not clinically apparent (neither palpable nor 
visible by imaging). Further subdivisions (a-c) describe how the tumor got detected 
(a: incidental tumor histological finding in 5% or less of resected tissue; b: incidental 
tumor histological finding in more than 5% of resected tissue; c: tumor diagnosed 
through a needle biopsy, for example because of an elevated PSA-level).  
T2 represents a tumor which is confined within the prostate. The subdivisions (a-c) 
refer to the extent of the tumor (a: tumor involves one half of one lobe or less, b: 
tumor involves more than half of one lobe, but not both lobes, c: tumor involves both 
lobes).  
In T3 classification level, the tumor extends through the prostatic capsule. T3a 
indicates an extracapsular extension (uni- or bilateral), in T3b the tumor infiltrates the 
seminal vesicles.  
The T4 classification indicates that the tumor is fixed or has invaded adjacent 
structures other than seminal vesicles: bladder neck, external sphincter, rectum 
and/or levator muscles and/or is fixed to the pelvic wall. 
N is the abbreviation for node (regional lymph nodes). NX implies that the regional 
lymph nodes cannot be assessed. N0 indicates that there are no regional lymph 
node metastases and N1 represents the fact that regional lymph node metastases 
exist.  
Distant metastases are abbreviated with M. If distant metastases cannot be 
assessed, it is classified as MX. M0 describes the absence of distant metastases and 
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M1 describes the presence. M1a classifies non-regional lymph node metastases, 
M1b osseous and M1c other metastases. 
The use of the C-factor is optional and reflects the validity of classification according 
to the diagnostic methods employed. 
This classification method is not very reliable due to low sensitivity and low specificity 
(Bostwick 1999; Wittekind, Sobin, and Klimpfinger 2005; Malayeri and Steger 1996). 
 
There are three kinds of therapy approaches for prostate cancer: radical 
prostatectomy, radiotherapy and anti-androgen therapy (Selley et al. 1997; Chen, 
Clegg, and Scher 2009). 
The treatment for patients with hormone-sensitive metastatic disease consists of the 
depletion of testosterone concentration or orchiectomy, often in combination with an 
anti-androgen, which keeps the endogenous androgen from docking to the receptor 
(Chen, Clegg, and Scher 2009).  
Another treatment option suitable especially for older men with low grade disease is 
conservative management (Selley et al. 1997). It is also known as expectant 
management or “watchful waiting” and implies no active treatment until the patient 
shows symptoms from outlet obstruction or metastatic disease. Patients are checked 
up regularly to assess disease development and to discuss treatment options 
(Chodak 1994). 
 
1.3. Molecular epidemiology 
 
The term „molecular cancer epidemiology“ was defined by Perera and Weinstein in 
1982 as an approach in cancer research, in which advanced laboratory methods are 
used in combination with analytical epidemiology to determine at the biochemical or 
molecular level specific exogenous agents or host factors playing a role in human 
cancer pathogenesis (Perera and Weinstein 1982). 
Molecular epidemiology can facilitate cancer prevention through the early 
identification of “at risk” populations with a higher susceptibility and through the 
improvement of the exposure assessment. A wide range of biomarkers should be 
incorporated into epidemiologic studies to assess individual exposure, dose, 
preclinical effects and susceptibility to carcinogens (Perera and Weinstein 2000).  
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One of the achievements of molecular epidemiology is the insight it has provided into 
inter-individual variations in human cancer risk and the extensive interactions 
between environmental factors and inherited or acquired susceptibility factors in the 
development of cancer (Perera 1997). 
 
The biomarkers have been generally categorized into four categories: (1) internal 
dose, (2) biologically effective dose, (3) preclinical biologic effects and (4) biomarkers 
of susceptibility (Perera and Weinstein 1982; Perera and Weinstein 2000).  
Biomarkers of internal dose consider individual differences in absorption, 
metabolism, bioaccumulation or excretion of a substance or its metabolites and 
indicate the actual level within the body or specific tissues. Examples are: cotinine, a 
metabolite of nicotine in serum or urine, resulting from cigarette smoke exposure; 
and urinary levels of 1-hydroxypyrene deriving from exposure to polycyclic aromatic 
hydrocarbons (PAHs) or aflatoxin B1 (AFB1) levels in urine from reflecting dietary 
sources. 
Markers of internal dose do not indicate the amount to which a given compound has 
interacted with critical cellular targets. To solve this problem, assays have been 
developed to measure the biologically effective dose of a substance, i. e. the amount 
of activated substance that has actually reacted with the critical cellular 
macromolecules, for example DNA, RNA or proteins in the blood.  
The biomarker of early or preclinical biologic effects resulting from exposure reflects 
following events in the multi-step progress of carcinogenesis. It is measured directly 
in target tissues or for example in white blood cells. Representative biomarkers 
determine various types of genotoxicity, including chromosomal aberrations, small 
deletions and point mutations. For example, mutations of the p53 tumor suppressor 
gene or the ras oncogene are common events in human cancerogenesis.  
The fourth and last category of biomarkers is that of inherited or acquired variations 
in host susceptibility, modulating the individual response to environmental 
carcinogens. Many different factors, in addition to exposure to a carcinogen, 
influence the probability that a tumor will develop in a certain individual. Examples of 
susceptibility factors are interindividual differences in the metabolism of carcinogenic 
chemicals, DNA repair or nutritional, hormonal or immunologic factors (Perera and 
Weinstein 2000). Genetic factors that influence cancerogenesis are extremely 
variable. Some mutations are rare, dominant and highly penetrant. Examples for 
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cancer developments affected by such a mutation are Retinoblastoma or Wilms’ 
tumors. More common genetic traits are often in combination with a low individual 
risk and influence like the metabolic activation or detoxification of carcinogenic 
chemicals (Perera 1997). The detection of these low-penetrance genes is important 
for cancers that are associated with lifestyle factors like tobacco, alcohol or diet 
(Kotnis, Sarin, and Mulherkar 2005). 
 
Latest revolutionary events for the practice of molecular epidemiology were the 
completion of the Human Genome Project and the HapMap Project, together with 
advances in high-throughput genotyping ability.  
The focus of molecular epidemiology in the future will lie on systems biology 
(integration of interactions in biological systems from diverse experimental sources); 
DNA, RNA or tissue-based microarrays; the investigation of epigenetic mechanisms 
and the role of MicroRNAs in cancer risk.  
The basic questions in the science of molecular epidemiology stay the same: Why 
did this person get this disease at this particular time? Was it preventable? Was it 
predictable (Spitz and Bondy 2010)?  
 
1.3.1. Single nucleotide polymorphism 
 
A single nucleotide polymorphism (SNP) is a stable inherited substitution of a single 
nucleotide. It has a minor allele frequency (MAF) of 1% or more in at least one 
population. Compared to polymorphisms like insertion or deletion of a nucleotide, a 
SNP is the most common sequence variation in the human genome (Kruglyak and 
Nickerson 2001; Risch 2000; Knippers 1995). Other polymorphisms are variable 
numbers of short tandem repeats (STR, 2-6 bp long) or tandem repeats. The 
variability in the number of a whole functional gene unit (exon, gene) is called CNV - 
copy number variation. This term also includes deletion (Kubistova, Mrazek, and 
Petrek 2009).  
Extrapolation of the existing data leads to a total number of over 15 million SNPs in 
the human genome, even more when many populations and their specific 
SNPs are included (Salisbury et al. 2003). SNPs are spread throughout the whole 
genome and can be found at least, on average, every 0.3–1 kilobases (kb; Schork, 
Fallin, and Lanchbury 2000).  
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While most SNPs are silent and do not change the function or expression of a gene, 
an estimated number of 50,000 to 250,000 of them will actually confer small to 
moderate biological effects (Chanock 2001). A SNP in a coding region may directly 
influence a relevant protein while a SNP in a promotor region can impact gene 
expression (Krawczak, Reiss, and Cooper 1992; Drazen et al. 1999). SNPs with 
functional consequences are expected to have lower allele frequencies. In fact, the 
majority of SNPs in a coding region causing an amino acid change have an allele 
frequency of below 5% (Kruglyak and Nickerson 2001).  
Persons who carry a particular allele at one site often predictably carry specific 
alleles at other proximate variant sites, known as linkage disequilibrium (LD). Blocks 
of SNPs in the same chromosomal region are not inherited randomly, rather as a 
combination of polymorphic alleles, known as haplotype blocks. Evaluation of 
markers inherited on a haplotype reduces the complexity of analysing SNPs in a 
gene or locus (International HapMap Consortium 2005; Erichsen and Chanock 
2004). 
This block-like structure of LD and the existence of areas of low or high 
recombination rate lead to the identification of tagging SNPs (tSNPs), which can be 
used to predict with high probability the alleles at other co-segregating SNPs 
(Beckmann, Estivill, and Antonarakis 2007; International HapMap Consortium 2005). 
The continuing discovery of SNPs and the characterization of haplotype blocks in 
human populations are having an elementary impact on the molecular epidemiology 
of cancer. It represents a notable tool to investigate inter-individual differences in 
treatment responses and outcomes of specific cancers. Genetic variation studies can 
help reveal critical determinants in environmental exposure and cancer, which in the 
future can help to develop strategies for prevention and early intervention (Erichsen 
and Chanock 2004; Rebbeck et al. 2004). 
 
1.3.2. Molecular epidemiology of prostate cancer 
 
The suspicion that genetics play a key role in prostate cancer has been verified over 
the past twenty years due to family-based linkage studies, twin studies and molecular 
epidemiologic studies. It was found that prostate cancer has a much more complex 
genetic basis than initially supposed (Schaid 2004).  
 10 
 
Familiy-based linkage studies confirmed familiy history as a well-established risk 
factor for the development of prostate cancer. A man who has a first-degree family 
member suffering from prostate cancer has 2.5 times higher risk developing the 
cancer himself than a man without family history.  
The highest risk exists, if more than one first-degree family member is affected and 
the cancer was diagnosed before 60 years of age (Johns and Houlston 2003). 
If at all, rare dominant susceptibility genes with high-penetrance account only for a 
small fraction of the observed genetic predisposition to prostate cancer. Linkage 
studies raise the possibility that prostate cancer is more likely influenced by a 
combination of common genetic polymorphisms of low-penetrance.   
The pattern of this inheritance follows Mendelian segregation as an autosomal 
dominant susceptibility trait (Shand and Gelmann 2006).  
Several prostate cancer susceptibility loci like HPC1, HPCX, PCAP and HPC20 have 
been identified. The AURKA gene (which encodes for AURKA) is located in the 
HPC20 prostate cancer susceptibility locus at 20q13 (Berry et al. 2000). 
 
1.3.3. Aurora kinase A 
 
The Aurora kinase family (A, B and C) consists of highly conserved serine/threonine 
protein kinases. They are involved in several mitotic events: regulation of spindle 
assembly checkpoint pathway, function of centrosomes and cytoskeleton, and 
cytokinesis. An aberrant expression of these kinases may lead to the development of 
cancer (Kollareddy et al. 2008). 
Aurora kinase A is also known as AURKA, aurora2, STK 15 (serine/threonine kinase 
15), BTAK (breast tumor-amplified kinase) or hARK1 (aurora related kinase; Feik et 
al. 2009; Zhou et al. 1998; Sakakura et al. 2001). It consists of 403 amino acids and 
has a molecular weight of approximately 46 kD (Zhou et al. 1998).  
Aurora kinase A is located in metaphase and anaphase of the mitosis at the 
centrosome, spindle poles and the spindle itself. In telophase, it is located primarily at 
the spindle poles (Bischoff et al. 1998). It is required for multiple crucial events during 
mitosis, such as mitotic entry, separation of centriole pairs, accurate bipolar spindle 
assembly, alignment of chromosomes to the metaphase plate and completion of 
cytokinesis (Marumoto et al. 2003). Defects in these processes can lead to 
centrosome abnormalities (larger diameter, elevated number and abnormal structure) 
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and aneuploidy, which contributes to genomic instability. In the vast majority of 
metastatic and invasive prostate carcinomas, centrosomes are structurally and 
numerically abnormal. These defects increase relatively with Gleason grade and with 
genomic instability (Pihan et al. 2001).   
Aurora kinase A is over-expressed in prostate tumors and in PINs. Overexpression in 
primary clinical prostate cancers correlates with tumorigenicity, clinical staging, 
surgical margin status and seminal vesicle invasion. A targeted inhibition of Aurora 
kinase A represents a possible approach toward prostate cancer therapy (Lee et al. 
2006). 
AURKA was also found to be over-expressed in breast tumors (Zhou et al. 1998), in 
human tumor cell lines of lung, colon and melanoma origin (Bischoff et al. 1998), in 
pancreatic tumors and cell lines, and in gastric cancers (Sakakura et al. 2001).  
 
1.4. Aim of the study 
 
The hospital based case-control study “Molecular Epidemiology of Prostate Cancer” 
was arranged at the Division of Applied and Experimental Oncology (Institute of 
Cancer Research, KIM1, Medical University of Vienna) in cooperation with the 
Departments of Urology of the Medical University of Vienna, Sozialmedizinisches 
Zentrum Ost and Sozialmedizinisches Zentrum Süd. The study population of this 
ongoing study consists of 550 BPH controls and 1027 prostate cancer cases 
recruited from these three hospitals in Vienna. 
The aim of the present study was to explore whether any of the four genotyped SNPs 
(rs2180691, rs8117896, rs1468055 and rs1476394) within the AURKA gene shows 
an association with prostate cancer risk. 
The ultimate goal is to create a polygenic model of prostate cancer susceptibility to 
identify high-risk individuals. The identification of these persons may furnish a basis 
for individualized therapy and chemoprevention.  
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2. Material and Methods 
 
2.1. Study population 
 
550 age-matched control patients and 1027 patients with histologically verified and 
previously untreated prostate cancer participated in this study.  
The controls suffered from lower urinary tract symptoms due to benign prostatic 
hyperplasia (BPH). In the control group, prostate cancer was excluded either 
clinically by negative digital rectal examination (DRE) and negative serum PSA or 
histologically by transrectal ultrasound (TRUS) guided biopsies or transurethral 
resection of the prostate. BPH is a very common non-malignant alteration of the 
prostate and is not a precursor of prostate cancer. The case group consisted of 
patients with newly diagnosed, histologically verified prostate cancer. Prostate 
carcinoma was diagnosed by TRUS-guided biopsies in all case patients. Suspicious 
findings on DRE and/or an elevated serum PSA-level were indications for prostate 
cancer.  
The blood for DNA extraction was collected from the study participants before any 
other treatments. 
A written consent was obtained from each participant and the study was approved by 
the institutional review boards. 
 
2.2. Genomic DNA isolation  
 
Human genomic DNA was purified according to the QIAamp® Blood Midi Kit Spin 
control (QIAGEN, Hilden, Germany). 2 ml of each whole blood sample were added to 
200 µl QIAGEN Protease respectively and mixed briefly. 2.4 ml lysis Buffer AL were 
added and this mixture was incubated in the water bath at 70°C for about thirty 
minutes. After adding 2 ml ethanol for molecular biology (99.8%) and mixing to obtain 
a homogenous solution, half of the solution was transferred onto the QIAamp Midi 
column and centrifuged at 1850 x g for three minutes. This step was repeated with 
the second half of the solution. The DNA bound to the column was washed with 2 ml 
Buffer AW1 (centrifuged at 4500 x g for two minutes) and 2 ml Buffer AW2 
(centrifuged at 4500 x g for eighteen minutes). The purified DNA was eluted with 300 
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µL Elution Buffer AE, incubated at room temperature for five minutes and then 
centrifuged at 4500 x g for seven minutes. 
DNA concentration was measured spectrophotometrically at a wavelength of 230 nm 
using the NanoDrop ND-1000 Sprectrophotometer (PEQLAB Biotechnologie GMBH, 
Erlangen, Germany). DNA samples were diluted with AE Buffer to a working dilution 
of 10 ng/µl and stored at –80°C.  
 
2.3. SNP selection 
 
The four single nucleotide polymorphisms rs2180691, rs8117896, rs1468055 and 
rs1476394 are tagging SNPs picked out from the HapMap database (CEU 
population; www.hapmap.org).   
 
2.4. Genotyping of AURKA polymorphisms 
 
Genotyping was conducted on a 7500 Fast Real Time PCR System (Applied 
Biosystems, California, US) using standard TaqMan® SNP Genotyping Assays and 
TaqMan® Genotyping PCR Master Mix (containing all components except primers 
and probes).  
The TaqMan® pre-designed SNP Genotyping Assay (Applied Biosystems, California, 
US) was performed using MicroAmp® Fast Optical 96-Well Reaction Plates (Applied 
Biosystems, California, US) optimized for 10 µl reactions.  
The genotyping reaction for 10 µl volume mix contained 20 ng DNA (Table 1).  
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Table 1. Components of the genotyping reaction mix 
 
Amount 
 
Component 
 
5 µl 
 
TaqMan® Genotyping PCR Master Mix 
 
0.125 µl 
 
40 x TaqMan® SNP Genotyping Assay 
 
2.875 µl 
 
Aqua bidestillata sterilis (Fresenius Kabi, Graz, Austria) 
 
2 µl 
 
DNA 
 
Standard cycling conditions were two minutes of heating at 50°C, followed by ten 
minutes at 95°C for the activation of AmpliTaq Gold® DNA Polymerase. Forty cycles 
were performed under the conditions of fifteen seconds at 95°C for denaturation and 
one minute at 60°C for annealing and extending of primers. 
 
2.4.1. TaqMan® MGB probes and primers 
 
The TaqMan® SNP Genotyping assay consists of unlabeled pre-designed PCR 
primers (36 µM) and TaqMan® minor groove binder (MGB) probes (8 µM). The final 
concentration of primers was 450 nM and 100 nM of probes in the reaction (Table 2) 
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Table 2. Pre-designed TaqMan® probes for genotyping AURKA polymorphisms 
SNP 
 
Chr. 
Position 
Component 5’ dye Context sequence 3’ dye Allele 
 
rs2180691 
 
54397768 
 
Probe 1 
 
VIC® 
 
AAAGTGC[A/G]TCTTCTG 
 
NFQ/MGB 
 
T 
  
 
Probe 2 
 
FAM™ 
 
AAAGTGC[A/G]TCTTCTG 
 
NFQ/MGB 
 
C 
 
rs8117896 
 
54389471 
 
Probe 1 
 
VIC® 
 
AGCCAGG[C/T]ACAATGG 
 
NFQ/MGB 
 
G 
  
 
Probe 2 
 
FAM™ 
 
AGCCAGG[C/T]ACAATGG 
 
NFQ/MGB 
 
A 
 
rs1468055 
 
54399308 
 
Probe 1 
 
VIC® 
 
ACACATG[A/C]TCTAATG 
 
NFQ/MGB 
 
T 
 
 
 
 
Probe 2 FAM™ 
 
ACACATG[A/C]TCTAATG 
 
NFQ/MGB 
 
G 
 
rs1476394 
 
54380550 
 
Probe 1 VIC
® 
 
GCAGACA[C/G]CAAGCCA 
 
NFQ/MGB 
 
G 
  
 
Probe 2 FAM™ 
 
GCAGACA[C/G]CAAGCCA 
 
NFQ/MGB 
 
C 
 
All four SNPs are located in introns in the AURKA gene on 20q13.2d. 
 
2.4.2. Allelic Discrimination with TaqMan® MGB probes 
 
The Allelic Discrimination assay is a multiplexed end-point assay, which is able to 
detect variants of a single nucleic acid sequence using the 7500 Fast Real Time PCR 
System (Applied Biosystems, California, US; Applied Biosystems 2006a). 
The TaqMan® SNP Genotyping Assay consists of two primers for the amplification of 
the polymorphic sequence of interest and of two TaqMan® minor groove binder 
(MGB) probes for the discrimination between the two alleles of interest. Each probe 
has a reporter dye at the 5’ end (VIC® on allele 1 probe, FAM™ on allele 2 probe), 
which allows biallelic genotyping (Applied Biosystems 2006b). The minor groove 
binder at the 3’ end of the probes causes an increased melting temperature (Tm), 
which allows the use of shorter probes (Afonina et al. 1997; Kutyavin et al. 1997).  
A non-fluorescent quencher (NFQ) is located at the 3’ end of each probe. During the 
PCR, each TaqMan® MGB probe anneals to its complementary sequence between 
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the both primers. The close proximity of the NFQ to the reporter dye results in the 
absorption of the emission of VIC® or FAM™ by fluorescence resonance energy 
transfer (FRET). In the next step, the AmpliTaq Gold DNA polymerase extends the 
primers and cuts off the probe from the target DNA when arriving at a probe 
hybridized to the template. This causes a separation of the reporter dye and the non-
fluorescent quencher (Figure 2), thereby interrupting FRET (Applied Biosystems 
2006b). 
 
Figure 2. 5’ Nuclease assay process (Applied Biosystems 2006b) 
 
 
In Figure 3, the two possibilities of match and mismatch are shown. Even a single 
nucleotide mismatch between a probe and the sequence of interest may diminish the 
efficiency of probe hybridization, thus disabling the cleavage of the reporter dye from 
the probe. A mismatched probe is therefore displaced without cleavage from the 
AmpliTaq Gold DNA polymerase (Applied Biosystems 2006b).  
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Figure 3. Mismatch discrimination with 5’ Nuclease Assay (Applied Biosystems 2006a) 
 
 
 
 
The separation of the reporter dye from the non-fluorescent quencher leads to an 
increase in fluorescence signals of VIC® and/or FAM™ during each PCR-cycle. 
Allelic discrimination represents an end-point determination with three possible 
results: (1) an increase of VIC® fluorescence signal represents homozygousity for 
allele 1, (2) an increase of FAM™ homozygousity for allele 2 or (3) a heterozygous 
genotype correlates with both signals present at the end-point determination (Table 
3; Applied Biosystems 2006b). 
 
 
 Table 3. Correlation between fluorescence signals and  
genotypes (based on Applied Biosystems, 2006b) 
 
Substantial increase in: 
 
Indication: 
 
Only VIC fluorescence 
 
Homozygousity for allele 1 
 
Only FAM fluorescence 
 
Homozygousity for allele 2 
 
Both fluorescence signals 
 
Heterozygousity for both alleles 
 
 
The increase in the fluorescence of VIC® or FAM™ associated with the TaqMan® 
probes is determined by the sequence detection software (SDS). This software 
produces a scatter plot, in which corresponding normalized reporter (Rn) values are 
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grouped into three genotype clusters: homozygous for allele 1, homozygous for allele 
2 and heterozygous. No template controls (NTCs) are used to measure the 
background signal (Applied Biosystems 2006a). 
 
2.5. Statistical analysis 
 
Genotypic counts of controls were tested for Hardy-Weinberg equilibrium (HWE) 
using a χ2-test. Haplotype estimates were determined and the frequencies of the 
most common haplotypes were derived using the program FASTPHASE (Scheet and 
Stephens 2006).  
Multiple logistic regression was applied to compare individuals of the case group 
against the control group. Separate models were estimated where each of the four 
polymorphisms described in Table 2 was included as three-level factor (homozygous 
wild type, heterozygous, homozygous polymorph) and each haplotype was included 
as explanatory variable. Age was identified as confounding variable. Odds ratios 
(ORs) and 95% confidence intervals (CIs) were estimated for each polymorphism 
and haplotype; reference categories were wild type and the most frequent haplotype, 
respectively.  
Analysis of data was performed using the software R Version 2.9.0 (R Development 
Core Team 2009). All p-values are 2-sided; p-values <0.05 were considered to be 
statistically significant. 
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3. Results 
 
3.1. Study population 
 
In a total study population of 1577 male subjects, demographic variables and 
smoking status were analysed. The control group consisted of 550 BPH patients, the 
case group of 1027 prostate cancer patients.  
The age indication is divided into four groups: subjects younger than 65, younger 
than 70, younger than 75 and 75 or older (Table 4). The control group had a 
statistically significant (p<0.0001) older age (67.01 years of age) than the case group 
(63.7).   
 
 Table 4. Age distribution 
 
Age 
 
Control (absolute value) 
 
Control (%) 
 
Cases (absolute value) 
 
Cases (%) 
 
Total 
 
< 65 
 
223 
 
40.55 
 
555 
 
54.04 
 
778 
 
< 70 
 
118 
 
21.45 
 
248 
 
24.15 
 
366 
 
< 75 
 
88 
 
16 
 
161 
 
15.68 
 
249 
 
>= 75 
 
121 
 
22 
 
63 
 
6.13 
 
184 
 
Mean 
 
67.01 
 
63.7 
 
 
Sd 
 
8.93 
 
7.63 
 
 
95% CI 
 
49.5-84.52 
 
48.75-78.66 
 
 
 
In Table 5 and Figure 4 the distribution of the Gleason scores is shown. The most 
frequent Gleason score in the case group is 6 (30.87%), followed by 7 (26.48%) and 
5 (12.07%). 141 Gleason score indications were missing (13.73%). The mean 
Gleason score is 6.51. 
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 Table 5. Distribution of the Gleason scores 
   
Gleason score 
  
Missing 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
Cases (absolute value) 
 
141 
 
3 
 
8 
 
13 
 
124 
 
317 
 
272 
 
93 
 
38 
 
18 
 
Cases (%) 
 
13.73 
 
0.29 
 
0.78 
 
1.27 
 
12.07 
 
30.87 
 
26.48 
 
9.06 
 
3.7 
 
1.75 
 
Mean 
 
6.51 
 
 
 Figure 4. Distribution of the Gleason scores 
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Discrimination was also made according to the TNM grading system (Table 6; Figure 
5). More than half (50.15%) of the case group had a stage of T3b to T4 or regional 
lymph node metastases or distant metastases, and only 2.43% had a T1a 
classification.  
 21 
 
 Table 6. Distribution of TNM classification 
   
Stage 
  
Missing 
 
T1a 
 
T1b-T3a 
 
T3b-T4 or N or M 
 
Cases (absolute value) 
 
90 
 
25 
 
397 
 
515 
 
Cases (%) 
 
8.76 
 
2.43 
 
38.66 
 
50.15 
 
 
Figure 5. Distribution of TNM classification 
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A PSA level of up to 4.0 ng/mL is regarded as unremarkable. The majority of the 
control group (48.18%) had a PSA level under this threshold, while more than half of 
the case group (50.54%) had a level between 4 and 10 ng/mL (Table 7; Figure 6). 
These differences are statistically significant (p<0.0001). 
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 Table 7. Distribution of PSA-level 
 
PSA (ng/mL) 
 
Control (absolute value) 
 
Control (%) 
 
Cases (absolute value) 
 
Cases (%) 
 
Missing 
 
44 
 
8 
 
111 
 
10.81 
 
<4 
 
265 
 
48.18 
 
109 
 
10.61 
 
4 to 10 
 
169 
 
30.73 
 
519 
 
50.54 
 
>=10 
 
72 
 
13.09 
 
288 
 
28.04 
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The prostate weight of the study population was determined using TRUS. The control 
group did not have statistically significant (p=0.36) higher value (44.07 ml) than the 
case group (42.69 ml). The valid values, the mean prostate weight and the standard 
deviation are shown in Table 8. 
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 Table 8. Distribution, mean and standard deviation of prostate weight 
  
Control (absolute value) 
 
Control (%) 
 
Case (absolute value) 
 
Case (%) 
 
Valid 
 
302 
 
54.91 
 
534 
 
52 
 
Mean 
 
44.07g 
 
42.69g 
 
Sd 
 
21.93 
 
19.52 
 
 
Each participant of the study was interviewed about his smoking habits (Table 9). 
The majority of both groups (control: 44%, case: 40.7%) were former smokers. 
13.64% of the controls and 12.56% of the cases were current smokers. The results 
were not statistically significant.  
 
 Table 9. Distribution of smoking habits 
  
Control (absolute value) 
 
Control (%) 
 
Case (absolute value) 
 
Case (%) 
 
Missing 
 
30 
 
5.45 
 
88 
 
8.57 
 
Never 
 
203 
 
36.91 
 
392 
 
38.17 
 
Former 
 
242 
 
44 
 
418 
 
40.7 
 
Current 
 
75 
 
13.64 
 
129 
 
12.56 
 
 
Furthermore, the average consumed cigarette packs per year (Table 10) and the 
average starting age (Table 11) were evaluated. The case group smoked in average 
2.69 packs more in one year (31.18 packs) than the control group (28.49 packs). No 
differences could be detected considering the starting age. Both results showed no 
statistical significance.  
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 Table 10. Distribution, mean and standard deviation of consumed cigarette  
 packs per year 
  
Control (absolute value) 
 
Control (%) 
 
Case (absolute value) 
 
Case (%) 
 
Valid 
 
283 
 
51.45 
 
450 
 
43.82 
 
Mean 
 
28.49 
 
31.18 
 
Sd 
 
26.14 
 
28.42 
 
 
 Table 11. Distribution, mean and standard deviation of starting age  
  
Control (absolute value) 
 
Control (%) 
 
Case (absolute value) 
 
Case (%) 
 
Valid 
 
293 
 
53.27 
 
468 
 
45.57 
 
Mean 
 
18.79 
 
18.94 
 
Sd 
 
5.72 
 
6.18 
 
 
3.2. AURKA genotypes 
 
AURKA genotypes (rs2180691, rs8117896, rs1468055, rs1476394) were determined 
using TaqMan® MGB probes (Applied Biosystems, California, US). An end-point 
allelic determination was performed on the PCR products. Corresponding normalized 
reporter (Rn) values were grouped into four different clusters (homozygous for  
allele 1/wild type, homozygous for allele 2/polymorphic, heterozygous and no 
template controls/NTCs) and shown as points on a scatter plot. The graph location of 
the points is corresponding to the three different specific genotypes. 
Figure 7 shows a representative example of the allelic discrimination scatter plot for 
rs8117896. The PCR reaction mix contained a VIC-labelled probe for the C/G allele 
on the x-axis and a FAM-labelled probe for the T/A allele on the y-axis.  
 
 25 
 
Table 7. SNP rs8117896 allelic discrimination assay – example of a scatter plot 
 
The genotype distributions of the four analysed SNPs in AURKA were all found to be 
in HWE among controls. 
 
In Table 12, the frequency distribution of all four SNPs in controls and cases is 
shown. The homozygous wild type was applied as a reference category. Carriers of 
the heterozygous polymorphic genotype of rs2180691 had an OR of 0.92 (95% CI= 
0.74-1.15) and carriers of the homozygous polymorphic genotype had 1.06 (95% CI= 
0.73-1.53). For the rs8117896 heterozygous polymorphic genotype, the OR 
calculated relative to patients with the homozygous genotype was 0.89 (95% CI= 
0.71-1.13). For the polymorphic homozygous variant, the OR was 1.06 (95% CI= 
0.77-1.46). For rs1468055 heterozygous polymorphic genotype, the OR was 0.93 
(95% CI= 0.74-1.16) and for homozygous polymorphic genotype was 0.84 (95% CI= 
0.51-1.39). The fourth SNP rs1476394 had an OR of 1.03 (95% CI= 0.81-1.3) for the 
heterozygous polymorphic genotype and an OR of 0.96 (95% CI= 0.51-1.8) for the 
homozygous polymorphic genotype.  
No statistically significant association between the four SNPs and prostate cancer 
risk was found. 
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Table 12. Distribution of AURKA genotypes in association with prostate  
cancer risk (confounder: age) 
 
SNP 
 
Genotype 
 
Controls (%) 
 
Cases (%) 
 
OR 
 
95% CI 
 
p-value 
 
rs2180691 
 
G/G 
 
271 (49.27) 
 
525 (51.12) 
 
1 
 
 
 
 
  
G/A 
 
227 (41.27) 
 
401 (39.05) 
 
0.92 
 
0.74-1.15 
 
0.47 
  
A/A 
 
52 (9.46) 
 
101 (9.83) 
 
1.06 
 
0.73-1.53 
 
0.77 
 
rs8117896 
 
C/C 
 
192 (34.91) 
 
375 (36.51) 
 
1 
 
 
 
 
  
C/T 
 
275 (50) 
 
486 (47.32) 
 
0.89 
 
0.71-1.13 
 
0.35 
  
T/T 
 
83 (15.09) 
 
166 (16.17) 
 
1.06 
 
0.77-1.46 
 
0.73 
 
rs1468055 
 
C/C 
 
328 (59.64) 
 
636 (61.93) 
 
1 
 
 
 
 
  
C/A 
 
193 (35.09) 
 
347 (33.79) 
 
0.93 
 
0.74-1.16 
 
0.53 
  
A/A 
 
29 (5.27) 
 
44 (4.28) 
 
0.84 
 
0.51-1.39 
 
0.5 
 
rs1476394 
 
C/C 
 
381 (69.27) 
 
706 (68.74) 
 
1 
 
 
 
 
  
C/G 
 
152 (27.64) 
 
292 (28.43) 
 
1.03 
 
0.81-1.3 
 
0.83 
  
G/G 
 
17 (3.09) 
 
29 (2.83) 
 
0.96 
 
0.51-1.8 
 
0.9 
 
Stratified analysis according to Gleason score was calculated for patients with a 
Gleason score <7 and >=7 (Table 13). No statistically significant association was 
found. 
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Table 13. Distribution of AURKA genotypes in association with prostate cancer risk and discrimination 
between Gleason score <7 and >=7 (confounder: age) 
    
Gleason <7 
 
Gleason >=7 
 
SNP 
 
Genotype 
 
Controls 
(%) 
 
Cases  
(%) 
 
OR 
 
95% CI 
 
p-
value 
 
Cases  
(%) 
 
OR 
 
95% CI 
 
p-
value 
 
rs2180691 
 
G/G 
 
271  
(49.27) 
 
307 
(29.89) 
 
1 
 
 
 
 
 
218 
(21.23) 
 
1 
 
 
 
 
  
G/A 
 
227 
(41.27) 
 
239 
(23.27) 
 
0.94 
 
0.73- 
1.2 
 
0.61 
 
162 
(15.78) 
 
0.9 
 
0.68-
1.18 
 
0.45 
  
A/A 
 
52 
(9.46) 
 
60  
(5.84) 
 
1.04 
 
0-69-
1.57 
 
0.85 
 
41  
(3.99) 
 
1.07 
 
0.68-
1.69 
 
0.77 
 
rs8117896 
 
C/C 
 
192 
(34.91) 
 
228  
(22.2) 
 
1 
 
 
 
 
 
147 
(14.31) 
 
1 
 
 
 
 
  
C/T 
 
275 
(50) 
 
283 
(27.56) 
 
0.85 
 
0.66- 
1.1 
 
0.22 
 
203 
(19.77) 
 
0.95 
 
0.71-
1.26 
 
0.71 
  
T/T 
 
83 
(15.09) 
 
95  
(9.25) 
 
0.98 
 
0.68- 
1.4 
 
0.91 
 
71  
(6.91) 
 
1.15 
 
0.78- 
1.7 
 
0.49 
 
rs1468055 
 
C/C 
 
328 
(59.64) 
 
364 
(35.44) 
 
1 
 
 
 
 
 
272 
(26.49) 
 
1 
 
 
 
 
  
C/A 
 
193 
(35.09) 
 
213 
(20.74) 
 
1 
 
0.78-
1.29 
 
0.98 
 
134 
(13.05) 
 
0.81 
 
0.61-
1.07 
 
0.13 
  
A/A 
 
29 
(5.27) 
 
29  
(2.82) 
 
0.99 
 
0.57-
1.71 
 
0.96 
 
15  
(1.46) 
 
0.63 
 
0.33-
1.22 
 
0.17 
 
rs1476394 
 
C/C 
 
381 
(69.27) 
 
420 
(40.89) 
 
1 
 
 
 
 
 
286 
(27.85) 
 
1 
 
 
 
 
  
C/G 
 
152 
(27.64) 
 
169 
(16.46) 
 
1.02 
 
0.78-
1.33 
 
0.87 
 
123 
(11.98) 
 
1.03 
 
0.78-
1.38 
 
0.82 
  
G/G 
 
17 
(3.09) 
 
17  
(1.65) 
 
0.9 
 
0.45-
1.83 
 
0.78 
 
12 
 (1.17) 
 
0.95 
 
0.44-
2.08 
 
0.9 
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Stratified analysis according to age also showed no statistically significant 
association between the polymorphic alleles of the investigated SNPs and prostate 
cancer (Table 14). 
 
Table 14. Distribution of AURKA genotypes in association with prostate cancer risk and discrimination 
between age <=64 and >64 
   
Age <=64 
 
Age >64 
 
SNP 
 
Genotype 
 
Controls 
(%) 
 
Cases 
(%) 
 
OR 
 
95% CI 
 
p-
value 
 
Controls 
(%) 
 
Cases 
(%) 
 
OR 
 
95% CI 
 
p-
value 
 
rs2180691 
 
G/G 
 
120 
(21.82) 
 
292 
(28.43) 
 
1 
 
 
 
 
 
151 
(27.45) 
 
233 
(22.69) 
 
1 
 
 
 
 
  
G/A 
 
82  
(14.91) 
 
217 
(21.13) 
 
1.09 
 
0.78-
1.51 
 
0.62 
 
145 
(26.36) 
 
184 
(17.92) 
 
0.77 
 
0.56-
1.04 
 
0.09 
  
A/A 
 
21 
(3.82)  
 
46 
(4.48) 
 
0.9 
 
0.52-
1.57 
 
0.71 
 
31 
(5.64) 
 
55 
(5.35) 
 
1.16 
 
0.7- 
1.91 
 
0.57 
 
rs8117896 
 
C/C 
 
80 
(14.55) 
 
196 
(19.08) 
 
1 
 
 
 
 
 
112 
(20.36) 
 
179 
(17.43) 
 
1 
 
 
 
 
  
C/T 
 
113 
(20.55) 
 
278 
(27.07) 
 
1 
 
0.71-
1.41 
 
0.98 
 
162 
(29.45) 
 
208 
(20.25) 
 
0.82 
 
0.59-
1.14 
 
0.23 
  
T/T 
 
30 
(5.45) 
 
81 
(7.89) 
 
1.1 
 
0.67- 
1.8 
 
0.71 
 
53 
(9.64) 
 
85 
(8.28) 
 
1.06 
 
0.69-
1.62 
 
0.81 
 
rs1468055 
 
C/C 
 
126 
(22.91) 
 
353 
(34.37) 
 
1 
 
 
 
 
 
202 
(36.73) 
 
283 
(27.56) 
 
1 
 
 
 
 
  
C/A 
 
87 
(15.82) 
 
182 
(17.72) 
 
0.75 
 
0.54-
1.04 
 
0.08 
 
106 
(19.27) 
 
165 
(16.07) 
 
1.14 
 
0.84-
1.57 
 
0.4 
  
A/A 
 
10 
(1.82) 
 
20 
(1.94) 
 
0.71 
 
0.32-
1.56 
 
0.39 
 
19 
(3.45) 
 
24 
(2.34) 
 
1 
 
0.52-
1.95 
 
0.98 
 
rs1476394 
 
C/C 
 
157 
(28.55) 
 
375 
(36.51) 
 
1 
 
 
 
 
 
224 
(40.73) 
 
331 
(32.23) 
 
1 
 
 
 
 
  
C/G 
 
58 
(10.55) 
 
164 
(15.97) 
 
1.18 
 
0.83-
1.68 
 
0.36 
 
94 
(17.09) 
 
128 
(12.46) 
 
0.94 
 
0.68-
1.31 
 
0.72 
  
G/G 
 
8 
(1.45) 
 
16 
(1.56) 
 
0.83 
 
0.35-
1.99 
 
0.68 
 
9 
(1.63) 
 
13 
(1.27) 
 
1.34 
 
0.54-
3.33 
 
0.53 
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Overall, the analysed data showed no statistically significant association between the 
four investigated AURKA SNPs and prostate cancer risk.  
 
The minor allele frequencies (MAFs) in the control group of this study population 
were in concordance (rs8117896, rs1468055, rs1476394) with those reported in the 
HapMap database for the Caucasian subpopulation. SNP rs2180691 shows a small 
aberration from the database (Table 15). 
 
Table 15. MAF distribution of the AURKA SNPs in control group and in the 
HapMap database 
 
 
 
To explore multilocus associations, haplotype analyses were conducted for the four 
tagging SNPs (rs2180691, rs8117896, rs1468055, rs1476394) within AURKA. Again, 
corresponding adjustment for age was performed (Table 16).  
The most common haplotype (homozygous for wild type in all four SNPs: 1111) was 
set as a reference category. The results showed no statistical significance. 
 
SNP 
 
Chr. 
Position 
 
MAF  
(Control Group) 
 
MAF (HapMap database 
[Caucasian subpopulation]) 
 
rs2180691 
 
 
54397768 G  A 
 
0.301 
 
0.239 
 
rs8117896 
 
 
54389471 C  T 
 
0.401 
 
0.367 
 
rs1468055 
 
 
54399308 C  A 
 
0.228 
 
0.243 
 
rs1476394 
 
 
54380550 C  G 
 
 
0.169 
 
0.208 
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Table 16. Distribution of AURKA haplotypes (confounder: age) 
 
 
A haplotype analysis according to Gleason score was performed (Table 17). The 
major aberration from the reference in the group of Gleason score <7 was found in 
haplotypes 1333 (0.86; 95% CI= 0.62-1.19) and 3111 (1.1; 95% CI= 0.77-1.57); and 
in haplotypes 1131 (OR= 0.73; 95% CI= 0.54-1.0) and 1333 (OR=0.81; 95% CI= 
0.57-1.16) in the group of Gleason score >=7. 
No statistically significant association was found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haplotype 
 
Controls 
 
Cases 
 
OR 
 
95% CI 
 
p-value 
 
Percentage cases 
of total number 
 
1111 
 
444 
 
852 
 
1 
   
65.7 
 
3311 
 
240 
 
429 
 
0.94 
 
0.77-1.15 
 
0.53 
 
64.1 
 
1131 
 
135 
 
229 
 
0.89 
 
0.7-1.14 
 
0.36 
 
62.9 
 
1313 
 
91 
 
187 
 
1.08 
 
0.82-1.43 
 
0.58 
 
67.3 
 
1333 
 
92 
 
147 
 
0.85 
 
0.64-1.14 
 
0.27 
 
61.5 
 
3111 
 
68 
 
124 
 
0.99 
 
0.72-1.37 
 
0.96 
 
64.6 
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Table 17. Distribution of AURKA haplotypes and discrimination between Gleason score <7 
and >=7 (confounder: age) 
   
Gleason <7 
 
Gleason >=7 
 
Haplotype 
 
Controls 
 
Cases 
 
OR 
 
95% CI 
 
p-value 
 
Cases 
 
OR 
 
95% CI 
 
p-value 
 
1111 
 
444 
 
494 
 
1 
   
358 
 
1 
 
 
 
 
 
3311 
 
240 
 
248 
 
0.92 
 
0.74-1.15 
 
0.46 
 
181 
 
0.95 
 
0.74-1.21 
 
0.66 
 
1131 
 
135 
 
147 
 
0.99 
 
0.76-1.3 
 
0.91 
 
82 
 
0.73 
 
0.54-1.0 
 
0.05 
 
1313 
 
91 
 
105 
 
1.06 
 
0.77-1.45 
 
0.73 
 
82 
 
1.1 
 
0.79-1.55 
 
0.57 
 
1333 
 
92 
 
86 
 
0.86 
 
0.62-1.19 
 
0.36 
 
61 
 
0.81 
 
0.57-1.16 
 
0.25 
 
3111 
 
68 
 
79 
 
1.1 
 
0.77-1.57 
 
0.6 
 
45 
 
0.86 
 
0.57-1.3 
 
0.47 
 
Furthermore, stratified analysis according to age was performed. It revealed that 
carriers of the haplotype 1131 have a statistically significant lower prostate cancer 
risk (OR= 0.7021, 95% CI= 0.49599-0.99384, p-value 0.04606) before or at the age 
of 64 years (Table 18). 
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Table 18. Distribution of AURKA haplotypes and discrimination between age <=64 and >64 
  
Age <=64 
 
Age >64 
 
Haplotype 
 
Controls 
 
Cases 
 
OR 
 
95% CI 
 
p-value 
 
Controls 
 
Cases 
 
OR 
 
95% CI 
 
p-value 
 
1111 
 
181 
 
472 
 
1 
 
 
 
 
 
263 
 
380 
 
1 
 
 
 
 
 
3311 
 
98 
 
228 
 
0.89 
 
0.67-1.19 
 
0.44 
 
142 
 
201 
 
0.99 
 
0.75-1.3 
 
0.92 
 
1131 
 
65 
 
119 
 
0.7 
 
0.5-0.99 
 
0.05 
 
70 
 
110 
 
1.16 
 
0.82-1.65 
 
0.41 
 
1313 
 
36 
 
110 
 
1.17 
 
0.77-1-77 
 
0.46 
 
55 
 
77 
 
1.08 
 
0.73-1.6 
 
0.71 
 
1333 
 
36 
 
77 
 
0.82 
 
0.53-1.26 
 
0.36 
 
56 
 
70 
 
0.92 
 
0.61-1.37 
 
0.67 
 
3111 
 
21 
 
62 
 
1.13 
 
0.67-1.91 
 
0.64 
 
47 
 
62 
 
0.91 
 
0.6-1.39 
 
0.66 
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4. Discussion 
 
In this diploma thesis four intronic single nucleotide polymorphisms within the AURKA 
gene and their association with prostate cancer risk in an Austrian population were 
investigated. AURKA is located on HPC20, a region which is known to be a prostate 
cancer susceptibility locus (Berry et al. 2000). Therefore, AURKA is a target gene for 
molecular epidemiologic prostate cancer studies.  
The vast majority of metastatic and invasive prostate tumors show centrosome 
abnormalities. Because centrosomes control the mitotic chromosome segregation, 
they play an important role in the maintenance of genomic stability (Pihan et al. 
2001). 
AURKA is required for multiple crucial events during mitosis, such as mitotic entry, 
separation of centriole pairs, accurate bipolar spindle assembly, and alignment of 
chromosomes to the metaphase plate and completion of cytokinesis (Marumoto et al. 
2003). Centrosome abnormalities and aneuploidy resulting in genomic instability are 
the results of defects in these processes that may be due to over-expression of 
AURKA (Pihan et al. 2001). Two studies (Lee et al. 2006; Buschhorn et al. 2005) 
found that AURKA is over-expressed in PIN, in prostate tumors, as well as in prostate 
cancer cell lines. Buschhorn et al. found an over-expression in 29% of normal 
prostate glands, suggesting that it is an early event in carcinogenesis. The level of 
AURKA expression increases as prostate cells transform from normal to high-grade 
PIN to carcinoma. As a possible therapeutic approach, AURKA inhibitor VX680 
reduces prostate cancer cell survival. Combination with doxorubicin intensifies this 
effect (Lee et al. 2006).  
Until now, molecular epidemiologic studies concerning SNPs in AURKA gene and 
prostate cancer focused on polymorphism T31A (Phe31Ile; rs2273535). 
A functional analysis of the T31A polymorphism was conducted by Matarasso et al. 
This study showed an association of the heterozygous and the polymorphic 
homozygous genotype of rs2273535 with significant AURKA over-expression 
(Matarasso et al. 2007).  
Ewart-Toland et al. conducted a meta-analysis of fifteen case-control studies, mostly 
unpublished. Two prostate cancer case-control sets were included in this study. One 
nested case-control study population of the Physician’s Health Study, a cohort study 
with 501 cases and 501 controls (Chan et al. 2002), showed a statistically 
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insignificant increased prostate cancer risk (OR= 1.76, 95% CI= 1.01-3.04) for the 
homozygous AA genotype of rs2273535. In the second population consisting of 559 
cases and 534 population-based controls, no altered risk (OR= 0.91, 95% CI= 0.54 – 
1.55) was observed. Overall, this meta-analysis showed that carriers of the 
polymorphic AA genotype had a statistically significant increased risk of multiple 
cancers such as colon, breast, lung, prostate, non-melanoma skin, esophageal and 
ovarian cancer with an OR of 1.4, 95% CI= 1.22-1.59, p < 0.001 (Ewart-Toland et al. 
2005). It must be take into account that this kind of study has limitations. Publication 
bias cannot be excluded because positive results are more likely to be published. 
Ewart-Toland et al. tried to avoid this problem by using mainly unpublished studies. 
Another limitation is the different study-design of studies used in a meta-analysis. 
Eligibility criteria for inclusions of study participants were different among the studies 
used in the meta-analysis of Ewart-Toland et al. Furthermore, studies with 
population-based and hospital-based control groups were included. In general, the 
selection of a control group is a critical point in the design of molecular epidemiologic 
studies. Especially in prostate cancer studies, a population-based study design would 
be hampered by the uncertainty of underlying prostate cancer as this disease occurs 
at high frequency in the seventh to eighth decade of life. To adress this, we used 
hospital-based BPH controls, in which the absence of prostate cancer was confirmed 
either histologically or clinically. One can consider that using a control group 
consisting of men with BPH could be a limitation of the study because it is also a 
hormone-dependent disease. We consider BPH patients as an appropriate control 
group because it is generally accepted that this disease is neither a premalignant 
lesion nor a precursor carcinoma. Furthermore, the incidence of histological evidence 
of BPH is in the range of 70 – 80% in the seventh to eighth decade of life, so it is 
almost impossible to identify a population without BPH in this age group (Berry et al. 
1984, Gsur et al. 2002, Gsur et al 2000). We considered the use of hospital-based 
BPH controls as a strength of our studies, as well as the histological confirmation of 
prostate cancer in cases and the large sample size of 1027 cases and 550 controls. 
The present study is a supplement of a previously published molecular epidemiologic 
prostate cancer study investigating SNPs rs2273535 and rs8173 and their 
association with prostate cancer risk (Feik et al. 2009). Four additional intronic 
tagging SNPs (rs2180691, rs8117896, rs1468055 and rs1476394) and their 
association with prostate cancer risk were investigated in this study to cover the 
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whole AURKA gene with six different tag SNPs. To our knowledge, this is the first 
study to investigate these four SNPs and their association with prostate cancer risk. 
However, no statistically significant association was found. Stratified analysis 
according to age revealed that carriers of a certain haplotype (G/G genotype in 
rs2180691, C/C genotype in rs8117896, A/A genotype in rs1468055 and C/C 
genotype in rs1476394) had a statistically significant lower prostate cancer risk 
before or at the age of 64 years. Other results of the haplotype analysis showed no 
statistical significance. A statistical analysis combining the six SNPs investigated in 
both studies is planned to be conducted and published. 
In this study, MAFs were found to be in concordance with those reported in the 
HapMap database for the Caucasian population. The small aberration in MAF of 
rs2180691 from the HapMap database can be explained by the smaller sample size 
(n=226) compared to the present study (n=550).  
The aim of this molecular epidemiologic study is to find a reliable biomarker for 
prostate cancer risk. Because prostate cancer is a multi-factorial disease, many 
genetic variations are involved (Schaid 2004). To adress this, genome-wide 
association studies using SNP Arrays have been conducted recently or are currently 
under the way. Through this method, it is possible to investigate the effect of 
inherited genetic variation on cancer risk and to search for cancer risk loci without 
concentrating on single candidate genes. Furthermore small to modest effects of 
SNPs can be detected. Identification of genetic variants, which are strongly 
associated with prostate cancer, may form a basis for improved screening and 
chemoprevention. 
 36 
 
5. References  
 
 
Afonina I, Zivarts M, Kutyavin I, Lukhtanov E, Gamper H, Meyer RB. (1997) Efficient 
priming of PCR with short oligonucleotides conjugated to a minor groove binder. 
Nucleic Acids Research 25: 2657-2660 
 
Alexander F. (1999) International Handbook of prostate cancer edited by David Kirk: 
1-12. Haslemere: Euromed Communications Ltd. 
 
Applied Biosystems. (2006a) Allelic Discrimination Getting Started Guide. 
www.appliedbiosystems.com 
 
Applied Biosystems (2006b) TaqMan® SNP Genotyping Assays Protocol. 
www.appliedbiosystems.com 
 
Beckmann JS, Estivill X, Antonarakis SE. (2007) Copy number variants and genetic 
traits: closer to the resolution of phenotypic to genotypic variability. Nature Reviews. 
Genetics 8: 639-646 
 
Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, 
Thibodeau SN, Schaid DJ. (2000) Evidence for a prostate cancer-susceptibility locus 
on chromosome 20. American Journal of Human Genetics 67: 82-91 
 
Berry SJ, Coffey DS, Walsh PC, Ewing LL. (1984) The development of human 
benign prostatic hyperplasia with age. The Journal of Urology 132: 474-479. Quoted 
in Feik E, Baierl A, Madersbacher S, Schatzl G, Maj-Hes A, Berges R, Micksche M, 
Gsur A. (2009) Common genetic polymorphisms of AURKA and prostate cancer risk. 
Cancer Causes & Control: CCC 20: 147-152 
 
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, 
Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD. (1998) A 
homologue of Drosophila aurora kinase is oncogenic and amplified in human 
colorectal cancers. The EMBO Journal 17: 3052-3065 
 
Bostwick D. (1999) International Handbook of prostate cancer edited by David Kirk: 
13-42. Haslemere: Euromed Communications Ltd. 
 
Buschhorn HM, Klein RR, Chambers SM, Hardy MC, Green S, Bearss D, Nagle RB. 
(2005) Aurora-A over-expression in high-grade PIN lesions and prostate cancer.  
The Prostate 64: 341-346 
 
Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. (2002) 
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of 
advanced-stage prostate cancer.  
Journal of the National Cancer Institute 94: 1099-1106 
 
Chanock S. (2001) Candidate genes and single nucleotide polymorphisms (SNPs) in 
the study of human disease. Disease Markers 17: 89-98. Quoted in Rebbeck TR, 
Ambrosone CB, Bell DA, Chanock SJ, Hayes RB, Kadlubar FF,  
 
 37 
 
Chen Y, Clegg NJ, Scher HI. (2009) Anti-androgens and androgen-depleting 
therapies in prostate cancer: new agents for an established target.  
The Lancet Oncology 10: 981-991 
 
Chodak GW. (1994) The role of watchful waiting in the management of localized 
prostate cancer. The Journal of Urology 152: 1766-1768. Quoted in Scheet P, 
Stephens M. (2006) A fast and flexible statistical model for large-scale 
population genotype data: applications to inferring missing genotypes and haplotypic 
phase. American Journal of Human Genetics 78: 629-644 
 
Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, Israel E, 
Schork N, Silverman ES, Katz DA, Drajesk J. (1999) Pharmacogenetic association 
between ALOX5 promoter genotype and the response to anti-asthma treatment. 
Nature Genetics 22: 168-170 
 
Epstein JI. (2009) An Update of the Gleason Grading System.  
The Journal of Urology 183: 433-440 
 
Erichsen HC, Chanock SJ. (2004) SNPs in cancer research and treatment.  
British Journal of Cancer 90: 747-751 
 
Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson 
RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, 
StanfordJL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, ClaymanGL, 
Lippman SM, Lee JJ, Zheng W, Balmain A. (2005) Aurora-A/STK15 T+91A is a  
general low penetrance cancer susceptibility gene: a meta-analysis of multiple 
cancer types. Carcinogenesis 26: 1368-1373 
 
Feik E, Baierl A, Madersbacher S, Schatzl G, Maj-Hes A, Berges R, Micksche M, 
Gsur A. (2009) Common genetic polymorphisms of AURKA and prostate cancer risk. 
Cancer Causes & Control: CCC 20: 147-152 
 
Gallagher RP, Fleshner N. (1998) Prostate cancer: 3. Individual risk factors. CMAJ: 
Canadian Medical Association Journal = Journal De l'Association Medicale 
Canadienne 159: 807-813 
 
Gandellini P, Folini M, Zaffaroni N. (2009) Towards the definition of prostate cancer 
related microRNAs: where are we now? Trends in Molecular Medicine 15: 381-390 
 
Gleason DF, and Mellinger GT. (1974) Prediction of prognosis for prostatic 
adenocarcinoma by combined histological grading and clinical staging. The Journal 
of Urology 111: 58-64. Quoted in Epstein JI. (2009) An Update of the Gleason 
Grading System. The Journal of Urology 183: 433-440 
 
Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzl G, Madersbacher S, 
Marberger M, Vutuc C, Micksche M. (2000) A polymorphism in CYP17 gene is 
associated with prostate cancer risk. International Journal of Cancer 87: 434-437 
Gsur A, Preyer M, Haidinger G, Zidek T, Madersbacher S, Schatzl G, Marberger M, 
Vutuc C, Micksche M. (2002) Polymorphic CAG repeats in the androgen receptor 
gene, prostate-specific antigen polymorphism and prostate cancer risk. 
Carcinogenesis 23: 1647-1651 
 38 
 
Hackl M. (2004) Krebsinzidenz und Krebsmortalität in Österreich.  
Wien: Statistik Austria. 
 
International HapMap Consortium. (2005) A haplotype map of the human genome. 
Nature 437: 1299-1320 
 
Johns LE, Houlston RS. (2003) A systematic review and meta-analysis of familial 
prostate cancer risk. BJU International 91: 789-794 
 
Knippers, R. (1995) Molekulare Genetik. 6. Aufl. Stuttgart: Georg Thieme Verlag. 
 
Kollareddy M, Dzubak P, Zheleva D, Hajduch M. (2008) Aurora kinases: structure, 
functions and their association with cancer. Biomedical Papers of the Medical Faculty 
of the University Palacký, Olomouc, Czechoslovakia 152: 27-33 
 
Köllermann J, Sauter G. (2009) Trends in prostate biopsy interpretation.  
Der Urologe 48: 305-312 
 
Kotnis A, Sarin R, Mulherkar R. (2005) Genotype, phenotype and cancer: role of low 
penetrance genes and environment in tumour susceptibility.  
Journal of Biosciences 30: 93-102 
 
Krawczak M, Reiss J, Cooper DN. (1992) The mutational spectrum of single base 
pair substitutions in mRNA splice junctions of human genes: causes and 
consequences. Human Genetics 90: 41-54. Quoted in Schork NJ, Fallin D, 
Lanchbury JS. (2000) Single nucleotide polymorphisms and the 
future of genetic epidemiology. Clinical Genetics 58: 250-264 
 
Kruglyak L, Nickerson DA. (2001) Variation is the spice of life. Nature Genetics 27: 
234-236 
 
Kubistova Z, Mrazek F, Petrek M. (2009) Polymorphisms of the immune response 
genes: selected biological, methodical and medical aspects. Biomedical Papers of 
the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia 153: 93-102 
 
Kutyavin IV, Lukhtanov EA, Gamper HB, Meyer RB. (1997) Oligonucleotides with 
conjugated dihydropyrroloindole tripeptides: base composition and backbone effects 
on hybridization. Nucleic Acids Research 25: 3718-3723. 
 
Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. (2006) Targeting Aurora kinases for 
the treatment of prostate cancer. Cancer Research 66: 4996-5002 
 
Malayeri R, Steger G. (1996) Prostatakarzinom. Klinische Onkologie edited by ,  
Pirker R, Fiegl M, and Huber H., 327-330. Wien: Facultas Universitätsverlag. 
 
Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H. (2003) Aurora 
A kinase maintains the fidelity of early and late mitotic events in HeLa cells.  
The Journal of Biological Chemistry 278: 51786-51795 
 
 
 
 39 
 
Matarasso N, Bar-Shira A, Rozovski U, Rosner S, Orr-Urtreger A. (2007) Functional 
analysis of the Aurora Kinase A Ile31 allelic variant in human prostate.  
Neoplasia 9: 707-715. 
 
Mellinger, G T, D Gleason, and J Bailar. (1967) The histology and prognosis of 
prostatic cancer. The Journal of Urology 97: 331-337. Quoted in 
Epstein JI. (2009) An Update of the Gleason Grading System.  
The Journal of Urology 183: 433-440 
 
Newling D. (1999) International Handbook of prostate cancer edited by David Kirk: 
61-20. Haslemere: Euromed Communications Ltd. 
 
Parkin DM, Bray FI, Devesa SS. (2001) Cancer burden in the year 2000. The global 
picture. European Journal of Cancer (Oxford, England: 1990) 37: 4-66. 
 
Perera FP. (1997) Environment and cancer: who are susceptible?  
Science 278: 1068-1073 
 
Perera FP, Weinstein IB. (1982) Molecular epidemiology and carcinogen-DNAadduct 
detection: new approaches to studies of human cancer causation.  
Journal of Chronic Diseases 35: 581-600 
 
Perera FP, Weinstein IB. (2000) Molecular epidemiology: recent advances and future 
directions. Carcinogenesis 21: 517-524 
 
Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. (2001) Centrosome 
defects can account for cellular and genetic changes that characterize prostate 
cancer progression. Cancer Research 61: 2212-2219. 
 
R Development Core Team. (2009) R: A Language and Environment for Statistical 
Computing. http://www.R-project.org. 
 
Rebbeck TR, Ambrosone CB, Bell DA, Chanock SJ, Hayes RB, Kadlubar FF,  
Thomas DC. (2004) SNPs, haplotypes, and cancer: applications in molecular 
epidemiology. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the 
American Association for Cancer Research, Cosponsored by the American Society of 
Preventive Oncology 13: 681-687 
 
Risch NJ. (2000) Searching for genetic determinants in the new millennium.  
Nature 405: 847-856 
 
Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K, Shimomura 
K, Nakamura Y, Inazawa J, Abe T, Yamagishi H. (2001) Tumour-amplified 
kinase BTAK is amplified and overexpressed in gastric cancers with possible 
involvement in aneuploid formation. British Journal of Cancer 84: 824-831 
 
Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC. (2003) SNP and 
haplotype variation in the human genome. Mutation Research 526: 53-61 
 
Schaid, DJ. (2004) The complex genetic epidemiology of prostate cancer.  
Human Molecular Genetics 13: 103-121 
 40 
 
 
Scheet P, Stephens M. (2006) A fast and flexible statistical model for large-scale 
population genotype data: applications to inferring missing genotypes and haplotypic 
phase. American Journal of Human Genetics 78: 629-644 
 
Schork NJ, Fallin D, Lanchbury JS. (2000) Single nucleotide polymorphisms and the 
future of genetic epidemiology. Clinical Genetics 58: 250-264 
 
Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. (1997) Diagnosis, management 
and screening of early localised prostate cancer.  
Health Technology Assessment 1: 1-96 
 
Shand RL, Gelmann EP. (2006) Molecular biology of prostate-cancer pathogenesis. 
Current Opinion in Urology 16: 123-131 
 
Spitz MR, Bondy ML. (2010) The evolving discipline of molecular epidemiology of 
cancer. Carcinogenesis 31: 127-134 
 
Statistik Austria a. Österreichisches Krebsregister (Stand 24. 02. 2009, erstellt am 
28. 04. 2009). 
http://www.statistik.at/web_de/static/krebsinzidenz_neuerkankungen_pro_jahr_nach_
lokalisationen_und_geschlecht_o_021806.xls 
 
Statistik Austria b. Österreichisches Krebsregister (Stand 24. 02. 2009, erstellt am 9. 
03. 2009). 
http://www.statistik.at/web_de/statistiken/gesundheit/krebserkrankungen/krebsinzide
nz_im_ueberblick/020524.html 
 
Statistik Austria c. Todesursachenstatistik (Erstellt am 16. 06. 2009) 
http://www.statistik.at/web_de/static/gestorbene_2008_nach_todesursachen_alter_ 
und_geschlecht_021987.xls 
 
Vutuc C, Schernhammer ES, Haidinger G, Waldhör T. (2005) Prostate cancer and 
prostate-specific antigen (PSA) screening in Austria.  
Wiener Klinische Wochenschrift 117: 457-461 
 
Wittekind C, Sobin LH, Klimpfinger M. (2005) TNM-Atlas. Berlin/Heidelberg: Springer 
Verlag 
  
Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S. (1998) 
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy 
and transformation. Nature Genetics 20: 189-193 
 
 
Ich habe mich bemüht, sämtliche Inhaber der Bildrechte ausfindig zu machen und ihre Zustimmung 
zur Verwendung der Bilder in dieser Arbeit eingeholt. Sollte dennoch eine Urheberrechtsverletzung 
bekannt werden, ersuche ich um Meldung bei mir.  
 41 
 
6. Appendix 
 
6.1. Abstract 
 
 
The present diploma thesis is part of the project “Molecular Epidemiology of Prostate 
Cancer”, a collaboration of the Department of Applied and Experimental Oncology of 
the Institute of Cancer Research and the Departments of Urology of the Medical 
University Vienna, Sozialmedizinisches Zentrum Süd and Sozialmedizinisches 
Zentrum Ost. Aim of this study is to create a polygenetic model to identify high-risk 
patients and to open new perspectives in prevention and therapy of prostate cancer. 
Prostate cancer is the most common malign neoplasm in men in Austria.  
In this diploma thesis four single nucleotide polymorphisms (SNPs) within the AURKA 
gene were genotyped. AURKA (Aurora Kinase A), a serin/threonin protein kinase, is 
located on chromosome 20q13, a known prostate cancer susceptibility locus, and is 
involved in some crucial events during mitosis. Genetic polymorphisms in AURKA 
gene may contribute to interindividual differences in chromosomal stability and 
therefore influence the risk of prostate cancer.  
The study population of this ongoing study consists of 1027 prostate cancer cases 
and of 550 benign prostatic hyperplasia (BPH) controls. Four selected tagging SNPs 
(rs2180691, rs8117896, rs1468055, rs1476394) were determined using -T5’ 
nuclease TaqMan MGB Assay. Overall, no significant association could be found 
between the investigated SNPs and prostate cancer risk. 
However, a haplotype analysis revealed a reduced prostate cancer risk (OR: 0.7021; 
95% CI: 0.49599-0.99384) for men below 64 years of age with the GCAC haplotype. 
Further investigations in larger study populations are required to assess the influence 
of polymorphisms in the AURKA gene on prostate cancer risk. 
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6.2. Zusammenfassung 
 
Die vorliegende Diplomarbeit ist ein Teil des Projekts „Molekulare Epidemiologie von 
Prostatakrebs“, einer Zusammenarbeit der Abteilung für angewandte und 
experimentelle Onkologie des Instituts für Krebsforschung sowie der urologischen 
Abteilungen der Medizinischen Universität Wien, des Sozialmedizinischen Zentrums 
Süd und des Sozialmedizinischen Zentrums Ost.  
Ziel dieser Studie ist es, ein polygenetisches Modell zu entwickeln, um 
Hochrisikopatienten identifizieren zu können und neue Perspektiven in der 
Prävention und der Therapie des Prostatakrebses zu eröffnen.  
Prostatakrebs stellt die häufigste bösartige Neubildung bei Männern in Österreich 
dar.  
In dieser Diplomarbeit wurden vier Single Nucleotide Polymorphisms (SNPs), welche 
im AURKA-Gen lokalisiert sind, genotypisiert. Das Gen für AURKA (Aurora Kinase 
A), eine Serin/Threonin-Proteinkinase, befindet sich am Chromosom 20q13, einem 
bekannten Prostatakrebs-Suszeptibilitätslokus. AURKA ist an einigen 
ausschlaggebenden Vorgängen während der Mitose beteiligt. Genetische 
Polymorphismen im AURKA-Gen tragen zu interindividuellen Unterschieden in der 
Chromosomenstabilität bei und beeinflussen dadurch das Prostatakrebsrisiko.  
Die Studienpopulation dieser fortlaufenden Studie besteht aus 1027 
Prostatakrebsfällen und 550 Kontrollpatienten mit benigner Prostatahypoplasie 
(BPH). Vier ausgewählte tagging SNPs (rs2180691, rs8117896, rs1468055, 
rs1476394) wurden mit Hilfe des T5’ Nuclease TaqMan MGB Assay bestimmt. 
Zusammenfassend wurde kein signifikanter Zusammenhang zwischen den 
untersuchten SNPs und dem Prostatakrebsrisiko gefunden.  
Jedoch zeigte eine Haplotypenanalyse ein reduziertes Prostatakrebsrisiko (OR: 
0,7021; 95% CI: 0,49599-0,99384) für Männer unter 64 Lebensjahren mit einem 
GCAC Haplotyp.  
Weitere Untersuchungen in größeren Studienpopulationen sind nötig, um den 
Einfluss von Polymorphismen im AURKA-Gen auf das Prostatakrebsrisiko 
festzustellen.  
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